MARKET

ARCT

ARCT

Arcturus Therape
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.20
+0.90
+4.92%
Opening 11:07 07/07 EDT
OPEN
18.37
PREV CLOSE
18.30
HIGH
19.47
LOW
18.30
VOLUME
191.95K
TURNOVER
2.47M
52 WEEK HIGH
65.00
52 WEEK LOW
11.70
MARKET CAP
507.24M
P/E (TTM)
-2.5486
1D
5D
1M
3M
1Y
5Y
Arcturus gains on reports to draw takeover interest, blog report claims
Arcturus Therapeutics (NASDAQ:ARCT) is said to have been approached about a takeover by CSL Limited (OTCPK:CSLLY), a source reportedly told Street Insider, whose account added that it is "unclear if
Seekingalpha · 06/22 05:39
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 22, 2022--Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · 06/22 00:00
70 Stocks Moving In Monday's Mid-Day Session
 Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric low-grade glioma showed an overall response rate of 64%.
Benzinga · 06/13 16:10
Arcturus Therapeutics Holdings' (NASDAQ:ARCT) investors will be pleased with their strong 147% return over the last three years
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
Simply Wall St. · 06/10 10:38
Arcturus Therapeutics's Return On Capital Employed Overview
Benzinga Pro data, Arcturus Therapeutics (NASDAQ:ARCT) reported Q1 sales of $5.24 million. Earnings fell to a loss of $51.17 million, resulting in a 32.35% decrease from last quarter.
Benzinga · 06/06 15:11
41 Stocks Moving In Friday's Mid-Day Session
Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares rose 60.2% to $1.7136. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for experimental narcolepsy drug.
Benzinga · 05/27 18:13
AVDL, SIGA, PSHG and IOVA among mid-day movers
 Gainers: Avadel Pharmaceuticals (AVDL) +123%. SIGA Technologies (SIGA) +40%. Concert Pharmaceuticals (CNCE) +30%. Farfetch (FTCH) +25%. Allarity Therapeutics (ALLR) +25%. Merus N.V. (MRUS) +23%. Tenon Medical (TNON) +22%. Arcturus Therapeutics Holdings (A...
Seekingalpha · 05/27 16:56
--Goldman Sachs Adjusts Arcturus Therapeutics Holdings' Price Target to $8 from $14, Keeps Sell Rating
MT Newswires · 05/24 10:43
More
No Data
Learn about the latest financial forecast of ARCT. Analyze the recent business situations of Arcturus Therape through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

8.33%Strong Buy
41.67%Buy
33.33%Hold
16.67%Under-perform
0.00%Sell
Analyst Price Target
The average ARCT stock price target is 55.55 with a high estimate of 140.00 and a low estimate of 8.00.
High140.00
Average55.55
Low8.00
Current 19.24
EPS
Actual
Estimate
-1.72-1.29-0.86-0.43
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 154
Institutional Holdings: 22.26M
% Owned: 84.25%
Shares Outstanding: 26.42M
TypeInstitutionsShares
Increased
40
2.10M
New
15
577.48K
Decreased
43
851.37K
Sold Out
23
321.61K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.71%
Pharmaceuticals & Medical Research
+0.57%
Key Executives
Non-Executive Chairman/Independent Director
Peter Farrell
President/Chief Executive Officer/Director
Joseph Payne
Chief Financial Officer/Director
Andrew Sassine
Chief Operating Officer/Chief Scientific Officer
Padmanabh Chivukula
Other
Lance Kurata
Other
Kelly Lindert
Independent Director
James Barlow
Independent Director
Edward Holmes
Independent Director
Jing Marantz
Independent Director
Magda Marquet
No Data
No Data
About ARCT
Arcturus Therapeutics Holdings Inc. is a late-stage global clinical messenger ribonucleic acid (mRNA) medicines company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its mRNA platform, the Company's lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose levels. The Company's products under developmental stage using STARR technology are ARCT-021, ARCT-154 and ARCT-165. Its COVID-19 vaccine candidate, ARCT-021, which is based on its STARR technology platform is through Phase II clinical trials. Its LUNAR-FLU Vaccine consists of Liver Franchise ARCT-810 (LUNAR-OTC) and Lung Franchise ARCT-032 (LUNAR-CF).

Webull offers kinds of Arcturus Therapeutics Holdings Inc stock information, including NASDAQ:ARCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARCT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARCT stock methods without spending real money on the virtual paper trading platform.